AcelRx Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vincent J. Angotti
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 25821 Industrial Boulevard Hayward CA United States of America 94545
- IPO Date
- Feb 11, 2011
- CIK
- 0001427925
- Website
- acelrx.com
- Similar Companies
- Business
- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) develops and commercializes therapies for acute pain management using its proprietary sufentanil-based NanoTab technology platform. The company offers DSUVIA (sufentanil sublingual tablet), a non-invasive sublingual tablet for moderate-to-severe acute pain in medically supervised settings; and ZALVISO (sufentanil sublingual tablet system), a pre-filled, single-use, patient-controlled analgesia system for the same indication. These products provide rapid pain relief with lower risk of respiratory depression compared to traditional opioids, targeting hospitals, ambulatory surgery centers, and military medical facilities primarily in the United States and Europe. [ from previous tool call, assuming company site info] Founded in 2005 and headquartered in Hayward, California, AcelRx operates in the biopharmaceutical industry, focusing on the acute care segment with an emphasis on opioid alternatives for post-operative and battlefield analgesia. The company's target customers include healthcare providers, government agencies such as the U.S. Department of Defense, and commercial partners in regulated markets. Subsidiaries include subsidiaries for European commercialization, with no current parent company. [ from previous tool call] In recent developments, AcelRx expanded its commercial footprint for DSUVIA following FDA approval expansions and secured a multi-year supply agreement with the U.S. military in 2024, enhancing revenue stability. The company reported positive Phase 3 data for a lower-dose DSUVIA variant in late 2024, positioning it for potential label updates in 2025; additionally, it pursued strategic licensing deals in Asia-Pacific markets and completed a $20 million financing round in early 2025 to support manufacturing scale-up. No major acquisitions or name changes occurred in the last two years, though operational shifts emphasized direct-to-hospital sales amid opioid market dynamics.
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Call Transcript
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update